Results 211 to 220 of about 30,192 (236)

Early septal reduction therapy for patients with obstructive hypertrophic cardiomyopathy

Journal of Thoracic and Cardiovascular Surgery, 2022
This study was conducted to determine the influence of early septal reduction therapy (SRT) after referral on survival in patients with obstructive hypertrophic cardiomyopathy.We reviewed the patients with obstructive hypertrophic cardiomyopathy (resting pressure gradient ≥30 mm Hg or provoked pressure gradient ≥50 mm Hg) who were evaluated at our ...
Hao Cui, Brian Lahr, Joseph Dearani
exaly   +3 more sources

Age-Based Outcomes in Patients Who Underwent Septal Reduction Therapy

American Journal of Cardiology, 2023
There are no national data on age-based outcomes of septal reduction therapy. Using the National Inpatient Sample, we included all adult patients who underwent septal myectomy (SM) or alcohol septal ablation (ASA) from 2005 to 2019. The primary objective was to evaluate the in-hospital mortality and new permanent pacemaker (PPM) placement after SM and ...
M Fuad Jan
exaly   +4 more sources

Choice of Septal Reduction Therapies and Alcohol Septal Ablation

Cardiology Clinics, 2019
In patients with resting or provoked gradients and symptoms refractory to optimal medical therapy, alcohol septal ablation or surgical septal myectomy may be considered. Given the overall comparable outcomes after ablation and myectomy, there is, for many patients, equipoise between the two procedures.
Michael A Fifer
exaly   +3 more sources

Outcomes of surgical septal myectomy for obstructive hypertrophic cardiomyopathy after previous septal reduction therapy

Journal of Thoracic and Cardiovascular Surgery
To compare early and late outcomes of septal myectomy in patients with obstructive hypertrophic cardiomyopathy who presented with residual or recurrent left ventricular outflow tract (LVOT) obstruction after previous septal-reduction therapy (SRT).From January 1989 to March 2022, 145 patients underwent reintervention by septal myectomy for residual ...
Mackram Eleid, Brian Lahr, Joseph Dearani   +2 more
exaly   +3 more sources

Septal Reduction Therapy for Hypertrophic Obstructive Cardiomyopathy

Journal of the American College of Cardiology, 2018
Michael A Fifer
exaly   +3 more sources

Non-surgical septal reduction therapy in hypertrophic cardiomyopathy

Heart, 2017
### Learning objectives Hypertrophic cardiomyopathy (HCM) is an inherited disease characterised by otherwise unexplained hypertrophy of the myocardium. It is transmitted in an autosomal dominant pattern with variable penetrance, with an estimated phenotypic prevalence of up to 1 in 500.1 HCM is a highly heterogeneous disease with varied patterns of ...
Robert M, Cooper, Rodney H, Stables
openaire   +2 more sources

Indications for and Individualization of Septal Reduction Therapy

2014
The importance of left ventricular outflow tract obstruction in a large subset of patients with HCM and drug-refractory symptoms, as well as the value of septal reduction therapy (surgical myectomy or alcohol septal ablation), has been demonstrated.
Dmitriy N. Feldman, John S. Douglas, Srihari S. Naidu   +2 more
openaire   +1 more source

Costs and Healthcare Resource Utilization for Obstructive Hypertrophic Cardiomyopathy With Septal Reduction Therapy

Journal of Invasive Cardiology, 2022
Patients with obstructive hypertrophic cardiomyopathy (oHCM) and severe refractory symptoms may require invasive septal reduction therapies (SRTs), either surgical septal myectomy (SM) or transcatheter alcohol septal ablation (ASA). The main objective of this study was to quantify all-cause and oHCM-related healthcare resource utilization (HCRU) and ...
Michael Butzner, Martin Maron, Phil Sarocco, Chia-Chen Teng, Eric Stanek, Hiangkiat Tan, Laura Robertson   +6 more
openaire   +2 more sources

Timing of invasive septal reduction therapies and outcome of patients with obstructive hypertrophic cardiomyopathy

International Journal of Cardiology, 2018
Whether early vs. delayed referral to septal reduction therapies (SRT, alcohol septal ablation or surgical myectomy) bears prognostic relevance in hypertrophic obstructive cardiomyopathy (HOCM) is unresolved. We analyzed the impact of SRT timing on the outcome of HOCM patients.We followed 126 patients for 5 ± 4 years after SRT (mean age 53 ± 15 years ...
Cavigli L., FUMAGALLI, CARLO, MAURIZI, NICCOLO', Rossi A., Arretini A., Targetti M., PASSANTINO, SILVIA, Girolami F., Tomberli B., Baldini K., Tomberli A., Antoniucci D., Yacoub M. H., Marchionni N., Stefano P. L., Cecchi F., Olivotto I.   +16 more
openaire   +2 more sources